key: cord-0906203-tjjm60iu
authors: Hsieh, Ching-Lin; Werner, Anne P.; Leist, Sarah R.; Stevens, Laura J.; Falconer, Ester; Goldsmith, Jory A.; Chou, Chia-Wei; Abiona, Olubukola M.; West, Ande; Westendorf, Kathryn; Muthuraman, Krithika; Fritch, Ethan J.; Dinnon, Kenneth H.; Schäfer, Alexandra; Denison, Mark R.; Chappell, James D.; Baric, Ralph S.; Graham, Barney S.; Corbett, Kizzmekia S.; McLellan, Jason S.
title: Stabilized Coronavirus Spike Stem Elicits a Broadly Protective Antibody
date: 2021-10-16
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109929
sha: 52eca2aa0e5fe4c9680d99f9cef8610086b78bba
doc_id: 906203
cord_uid: tjjm60iu

Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use structure-guided protein engineering to remove the S1 subunit from the MERS-CoV spike (S) glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicits cross-reactive β-coronavirus antibody responses and protects mice against lethal MERS-CoV challenge. High-throughput screening of antibody secreting cells from MERS SS-immunized mice leads to discovery of a panel of cross-reactive monoclonal antibodies. Among them, antibody IgG22 binds with high affinity to both MERS-CoV and SARS-CoV-2 S proteins, and a combination of electron microscopy and crystal structures localizes the epitope to a conserved coiled-coil region in the S2 subunit. Passive transfer of IgG22 protects mice against both MERS-CoV and SARS-CoV-2 challenge. Collectively, these results provide proof-of-principle for cross-reactive coronavirus antibodies and inform the development of pan-coronavirus vaccines and therapeutic antibodies.

Current coronavirus vaccines primarily target immunodominant epitopes in the S1 subunit, which are 23 poorly conserved and susceptible to escape mutations, thus threatening vaccine efficacy. Here, we use 24 structure-guided protein engineering to remove the S1 subunit from the MERS-CoV spike (S) 25 glycoprotein and develop stabilized stem (SS) antigens. Vaccination with MERS SS elicits cross-reactive 26 β-coronavirus antibody responses and protects mice against lethal MERS-CoV challenge. High-27 throughput screening of antibody secreting cells from MERS SS-immunized mice leads to discovery of a 28 panel of cross-reactive monoclonal antibodies. Among them, antibody IgG22 binds with high affinity to 29 both MERS-CoV and SARS-CoV-2 S proteins, and a combination of electron microscopy and crystal 30 structures localizes the epitope to a conserved coiled-coil region in the S2 subunit. Passive transfer of 31

IgG22 protects mice against both MERS-CoV and SARS-CoV-2 challenge. Collectively, these results 32 provide proof-of-principle for cross-reactive coronavirus antibodies and inform the development of pan-33 coronavirus vaccines and therapeutic antibodies. 34

traces of all variants showed a major trimeric peak with some minor shoulder peaks, with the retention 133 volumes of the trimeric variants being similar to the base construct and mut11. 134

Next, we sought to examine the contribution of the individual substitutions comprising mut11 to 135 protein expression and thermostability by reverting each of the substitutions back to the wildtype residue. 136

Reverting K816R, H1020Q, H1146Y or V1150T increased the protein expression relative to mut11, 137 meaning these four substitutions in mut11 are dispensable. Thus, a new base construct containing 7 138 substitutions (mut7) was used for subsequent designs ( Figure S1B ). To test whether our structure-based 139 designs (previously tested individually on the mut11 background) have additive effects, we added a 140 disulfide design (T803C/K933C), a cavity filling design (S975M), or a combination of both designs 141 (S975M, T803C/K933C) on top of mut7. However, unlike the increase in expression for mut11, 142 T803C/K933C decreased the protein expression relative to mut7, but increased the Tm by 1.7 °C (Figure 143 S1C). S975M substitution not only boosted protein expression relative to mut7, but also enhanced the 144 thermostability. Combining both T803C/K933C and S975M on the mut7 backbone restored the 145 expression to a level similar to mut7 and increased Tm by 4.0 °C. After iterative screening of WT 146 reversions in mut7 S975M/T803C/K933C, we found that A918P and V1139F had adverse effects on 147 protein expression and thermostability (Figures S1D and S1E). Removal of A918P and V1193F resulted 148 in our first stabilized stem antigen, MERS SS.V1 (Figures S1B and S1C), containing 7 substitutions in 149 addition to the original 2P mutations (S975M, T803C/K933C, V958S, V983I, S1091E, L1094Q, 150 N1132Y, V1060P, L1061P). 151

To evaluate the viability of MERS SS.V1 as an immunogen, we investigated large-scale 152 production in FreeStyle 293-F cells, thermostability, and epitope integrity. After two consecutive runs of 153 SEC, MERS SS.V1 exhibited a monodispersed trimeric peak, with a yield of 2.2 mg from 1 L of cell 154 culture. The Tm of MERS SS.V1 is 59.9 °C, which is a 6.3 °C increase relative to mut11 ( Figure S1F  155 and S1G). mAb G4 is one of very few S2-directed antibodies showing neutralizing activity to CoV (Wang et al., 2015) . The binding kinetics of MERS SS.V1 to G4 IgG were comparable to those of 157 J o u r n a l P r e -p r o o f

We also examined the conformation of MERS SS.V1 complexed with G4 Fab by negative stain electron 159 microscopy (nsEM) analysis ( Figure S2C ). Although the images from 2D class averages of SS.V1 did 160 not resemble an elongated postfusion conformation, it was not clear that our stem-stabilized antigens 161 maintained a fully prefusion state. Taken together, these results suggest that MERS SS.V1 retains the 162 integrity of the known neutralization epitope and should be amenable to large-scale production. 163

Introducing disulfide linkages to lock viral glycoproteins in the prefusion conformation has 164 proven effective in class I viral fusion proteins such as RSV F, HIV-1 Env and Ebola GP (McLellan et al., 165 2013; Rutten et al., 2020; Sanders et al., 2013) . Although it was not successfully applied to the S2 subunit 166 of the SARS-CoV-2 S (Hsieh et al., 2020) , it was effective to lock the RBD from the S1 subunit to the S2 167 subunit and stabilize a closed S trimer conformation (Henderson et al., 2020; McCallum et al., 2020; 168 Xiong et al., 2020) . We thus explored feasibility of the disulfide design on MERS SS.V1. Three disulfide 169 designs, A838C/S1089C, S845C/A1096C and V898C/V1022C, were introduced individually or in 170 combination to stabilize the region proximal to the fusion peptide and central helix. With the addition of 171 V898C/V1022C, the protein expression level increased 1.3-fold relative to MERS SS.V1 and the Tm 172 increased by 4.0 °C (Figures 1F and S1F ). Upon combination with either A838C/S1089C or 173 S845C/A1096C substitutions, the protein expression levels increased 1.7-fold relative to MERS SS.V1 174 and the Tm increased by 6.3 °C. Notably, both constructs exhibited a sharp monodisperse trimeric peak 175 on SEC without any prominent shoulder peaks. This led to our best construct, MERS SS.V2, which 176 contains A838C/S1089C and V898C/V1022C added onto the MERS SS.V1 background. The large-scale 177 expression of MERS SS.V2 outperformed MERS SS.V1, yielding 9.5 mg from 1L of FreeStyle 293-F 178 cells ( Figure S1G) . 179

To evaluate the cross-reactive immunogenicity of MERS SS immunogens, we immunized BALB/cJ mice 181 with 0.4, 2, or 10 µg of MERS SS.V1 or SS.V2 or the maximally effective dose of 1 µg stabilized MERS 182 J o u r n a l P r e -p r o o f S ectodomain (MERS S-2P) (Pallesen et al., 2017) (Figure 2A ). All doses of both immunogens elicited 183 ~10 5 MERS S-2P-specific reciprocal endpoint binding titers at 2 weeks post-boost ( Figure 2B ). Both 184 MERS SS.V1 and SS.V2 elicited HCoV-HKU1, SARS-CoV, and SARS-CoV-2 2 S-2P-specific IgG that 185 trended toward dose-dependency; most notably at the 0.4 µg dose, heterotypic SARS and SARS-2 S-2P-186 specific binding IgG responses were more significant in mice immunized with SS.V1 compared to mice 187 immunized with SS.V2 (Figures 2C-E) . Conversely, neutralizing antibody responses against a 188 pseudotyped lentivirus reporter expressing MERS-CoV S were not dose-dependent. As expected, both SS 189 immunogens elicited significantly fewer neutralizing antibodies than MERS S-2P given the lack of the S1 190 subunit in the SS immunogens. While MERS SS.V1 elicited only modest baseline neutralizing antibody 191 responses (up to a geometric mean reciprocal ID 50 titer, GMT = 156), SS.V2 induced stronger 192 neutralization responses with GMT of 550 ( Figure 2F ). Altogether, these data corroborate that the 193 introduction of stabilizing disulfide bonds into the SS.V1 backbone promotes the production of more 194 potently neutralizing MERS-CoV S2-specific antibodies. Additionally, they underscore the importance of 195 targeting conserved epitopes to induce broad binding antibody responses. 196

In order to assess the ability of MERS stabilized stem immunogens to protect against lethal MERS-CoV 198 challenge, we immunized 288/330 +/+ mice (Cockrell et al., 2016) with 10 µg of MERS SS.V1 or S-2P, 199 adjuvanted with SAS at weeks 0, 3, and 9-inclusive of an additional boost to further promote cross- contrasting against PBS-immunized mice, which presented 2 x 10 6 geometric mean PFU per lung lobe 220 ( Figure 3F ). In line with trends of viral replication among SS.V1 and S-2P-immunized mice, at both 221 days 3 and 5 post-challenge there was little to no distinguishable pulmonary damage as evidenced by low 222 discoloration scores; indicating that both vaccines effectively protected against infection and lung disease 223 ( Figures 3G-H) . These findings emphasize the utility of eliciting protective immunity by targeting 224 epitopes outside of immunodominant and neutralization-sensitive S1 sites. 225

Next, we employed AbCellera's single B cell technology to isolate cross-reactive monoclonal antibodies 227 from the spleen, thymus and lymph nodes of mice immunized with MERS SS.V1 antigen. Using HCoV-228 HKU1 S-2P, SARS-CoV S-2P , MERS-CoV S-2P, and MERS SS.V1 as probes, 146 antibodies with a 229 diverse spectrum of specificities to the β-CoV S proteins were discovered. We selected for antibodies 230 exhibiting broader S reactivities, higher frequencies, and unique CDR3s in both heavy and light chains in 231 order to cover a wide distribution of the germline family. The selected IgGs were then expressed 232

HCoV-HKU1 S-2P, MERS-CoV S-2P, and SARS-CoV S-2P. IgG20, IgG23 and IgG62 demonstrated 234 cross-reactive binding to MERS-and SARS-CoV S with higher apparent affinity to the former ( Figure  235 S3A). Intriguingly, IgG21, IgG22 and IgG72 were also MERS-and SARS-specific, but the association 236 rates of these mAbs to SARS-CoV S were nearly 5-fold higher than to MERS-CoV S ( Figure S3B ). In 237 contrast, IgG12, IgG19 and IgG42 only bound to MERS-CoV S ( Figure S3C ). We also performed 238 competitive binding experiments with G4, the only MERS S2-targeted antibody with a structurally 239 defined epitope (Pallesen et al., 2017) . One third of selected mAbs (IgG20, IgG23 and IgG62) competed 240 with G4 binding to MERS-CoV S ( Figures S4A-B) . By contrast, IgG12, IgG19, IgG21, IgG22, IgG42 241

and IgG72 appeared to bind to regions outside of the G4 epitope. Although the initial screening from 242 single B cell technology showed that IgG7 reacted with HKU1 S-2P, IgG7 was shown to target a foldon 243 trimerization motif that was artificially linked to all of the S antigens and the control RSV F protein. Finally, we performed a nsEM analysis for one of the non-G4 competing antibodies, Fab20, complexed 245 with MERS-CoV S. In line with competitive binding data, the low-resolution reconstruction of the 246 complex indicated that Fab20 bound to a different site from the G4-binding loop at the bottom of the S2 247 subunit ( Figure S4C ). 248

IgG22 and the clonally related IgG72 are two of the cross-reactive antibodies that exhibited faster 250 association to SARS-CoV S than MERS-CoV S ( Figure S3B ). To determine the kinetics of their 251 interactions, we performed surface plasmon resonance experiments where we flowed Fab over S 252 ectodomain immobilized to a sensor chip. The binding affinity of Fab22 to MERS-CoV S was 253 comparable to those of SARS-CoV S and SARS-CoV-2 S, with K D values of 2.9 nM, 7.2 nM, and 6.7 254 nM, respectively ( Figures 4A-C) . However, Fab22 exhibited distinct binding kinetics to MERS-CoV S, 255 featuring a much slower on-rate and off-rate than SARS-CoV or SARS-CoV-2 S. We examined the 256 neutralization activities of selected mAbs against authentic MERS-CoV. IgG22 and IgG72 exhibited 257 J o u r n a l P r e -p r o o f potent neutralizing activity, with IC 50 values of 0.12 μg/ml and 2.45 μg/ml, respectively ( Figure 4D ). On 258 the other hand, IgG20, IgG21 and IgG42 showed no neutralization activity against MERS-CoV. 259

Interestingly, IgG22 and IgG72 failed to neutralize authentic SARS-CoV-2 ( Figure 4E ), which may be 260 due to the faster off-rate of IgG22 to SARS-CoV-2. However, we cannot rule out other possibilities, such 261 as differences in S density between the two viruses. 262

To investigate Fab22 and Fab72 binding sites on S, we performed negative stain electron microscopy 264 (nsEM) analysis for the Fab-S complexes. 2D classification showed three distinct densities for Fab22 265 attached to the S2 stalk region of MERS-CoV S-2P, a region that undergoes substantial conformation 266 changes during the pre-to-postfusion transition ( Figure S5A ). Interestingly, Fab72 also binds to a similar 267 region of S2 in proximity to HR2 ( Figure S5B ). Given that binding of HR2 could potentially prevent 268 virus-cell membrane fusion, we sought to determine a cryo-EM structure of Fab22 bound to MERS S-2P. 269

Resembling the nsEM analysis, we were able to see three distinct Fab densities from multiple 2D classes 270 ( Figure 4F ). The initial 3D reconstruction exhibited a single conformation of the S, with all three RBDs 271 in the down conformation. A total of 183,556 particles led to a 3.3 Å reconstruction with well-defined 272 side chain densities at the core of S2. Three Fab densities could be visualized at the bottom stalk of S2, 273 although one of the Fabs displayed a broader than usual Fab density. It is possible that the highly flexible 274 nature of the stalk-HR2 region could lead to broadened Fab density. Therefore, the initial set of particles 275 was subjected to two additional rounds of heterogeneous refinement to sort out 3D classes with diverse 276 Fab orientations. We were able to obtain a 3D reconstruction (3.3 Å) from about half of the total particles 277 (48.7%) demonstrating three distinct Fab densities bound to the S. Interestingly, both reconstructions 278 displayed three-RBD-down conformations. Focused refinement on the Fab22 densities was attempted, but 279 the Fab-S interface could not be resolved. SARS-CoV-2 neutralization by IgG22, we attempted to determine a high-resolution structure of Fab22 284 bound to SARS-CoV-2 S HexaPro, a prefusion-stabilized S (Hsieh et al., 2020) . The initial 3D 285 reconstruction exhibited a disc-shaped Fab density beneath the helical stalk of the globular ectodomain. 286

After two additional rounds of heterogeneous refinement, we were able to sort out two different 287 conformations of S: one-RBD-up at 4.0 Å (53% of the total particles) and three-RBD-down at 4.4 Å (31% 288 of the total particles) (Figures 5A-B) . Although Fab22 density was not well defined, the Fab binding site 289 on the S could be located to the helical stalk, which is only resolved in the full-length S model (PDB: 290 6XR8) ( Figure 5C ). Sequence alignments of the helical stalk show that, among the β-CoVs, HCoV-291 HKU1 is the least conserved in this region. This could explain why IgG22 has nearly no affinity to the 292

HCoV-HKU1 S. To further narrow down the binding site, we constructed two C-terminal truncations of 293 the S variants: ΔHR2 (1-1160) and Δstalk (1-1142). In line with the cryo-EM map, Fab22 retained the 294 affinity to HexaPro-ΔHR2 but completely lost the binding to HexaPro-Δstalk ( Figure 5D ). Collectively, 295 these data demonstrate that the conserved helical stalk region between residues 1142 and 1160 is an 296 epitope with the potential to elicit cross-reactive S2-targeted antibodies. 297

To gain molecular insight into the ability of Fab22 to bind both MERS-CoV S and SARS-CoV-2 S, we 299 determined crystal structures of Fab22 bound to either a MERS-CoV S peptide or a SARS-CoV-2 S 300 peptide containing the putative S2 epitope (Figures 6A-B and S6) . These structures 301 revealed that Fab22 can bind both MERS-CoV and SARS-CoV-2 S by engaging residues that are 302 conserved between both viruses. The Fab22 peptide interfaces each contain 3 key hydrophobic 303 interactions, formed by Leu1235, Phe1238 and Phe1239 in MERS-CoV S, and by Leu1152, Tyr1155 and 304

Phe1156 in SARS-CoV-2. These conserved residues occupy the same position in both structures, with 305

Phe1239/Phe1156 being sandwiched between CDRH3 Arg100c and CDRH1 Phe33, and 306 6C-D). In addition, the conserved Asp1236/Asp1152 forms a salt bridge with CDRH3 Arg100c, and the 308 conserved Glu1234/Glu1151 forms a salt bridge with CDRH2 Lys58 (Figures 6C-D) . The conservation 309 of these five positions in the Fab22 epitope provide a molecular basis for its cross-reactivity ( Figure 6E) . 310

The observed cross-reactivity of IgG22 to MERS-CoV and SARS-CoV-2 S suggested its ability to protect 312 against both viruses in vivo. We first assessed protection against a lethal dose of MERS-CoV using 313 mouse-adapted strain maM35c4 (Douglas et. al., 2018) in the 288/330 +/+ mouse model (Cockrell et al., 314 2016) ( Figure S7A ) and subsequently, for SARS-CoV-2, we utilized a BALB/c model (Dinnon et al., 315 2020; Leist et al., 2020) (Figure 7A) . In both models, 2 or 20 mg/kg IgG22 or 20 mg/kg MERS-CoV S2-316 directed mAb G4 (Wang et al., 2018) was passively transferred into mice and compared to mock-317 immunized, PBS control mice (Figures S7A and 7A) . Firstly, IgG22 protected against homotypic 318 MERS-CoV challenge in a dose-dependent fashion; 20 mg/kg of IgG22 and G4 significantly reduced 319 weight loss as compared to PBS control mice, which demonstrated an average loss of 14.1% of the initial 320 starting weight by day 5 post-challenge ( Figure S7B ). In contrast, there was no difference comparing 321 PBS-control mice and mice immunized with 2 mg/kg of IgG22 ( Figure S7B ). These results were 322 mirrored in assessments of lower airway viral replication and disease. On day 5 post-challenge, PBS 323 control mice had a geometric mean of 5.0 x 10 4 PFU/lobe and the 2 and 20 mg/kg IgG22 group had 70.5-324 fold and 6.7-fold less lung-resident MERS-CoV, respectively ( Figure S7D ). As well, discoloration of 325 lung tissues was completely inhibited in both the 20 mg/kg IgG22 and G4 groups but evidence of lung 326 discoloration was present in the 2 mg/kg IgG22-immunized and PBS-control mice by the fifth day post-327 challenge ( Figure S7C ). In the upper airway, by day 5, there was significantly less (8.7-fold) MERS-CoV 328 in nasal turbinates of mice that received 20 mg/kg IgG22 as compared to PBS-control mice; however 2 329 mg/kg IgG22 did not prevent upper airway MERS-CoV replication ( Figure S7E) . Notably, across all 330 measurements, there were similarities in the ability of mAbs G4 and IgG22 to protect against MERS-331 J o u r n a l P r e -p r o o f CoV-2, further suggesting these two S2-directed potently neutralizing antibodies provide homotypic 332 protection via a similar mechanism. 333

For SARS-CoV-2 challenge, mice were infected with 10 4 PFU SARS-CoV-2 MA10 (Leist et al., 334 2020) , 24-hours following IP treatments. Mice immunized with 20 mg/kg of mAb G4, 2 mg/kg of IgG22, 335 and PBS all demonstrated similar trends in weight loss kinetics-losing on average 17.3%, 14.6%, or 336

19.0% of the initial starting weight, respectively-by day 4 post-challenge ( Figure 7B ). In contrast, mice 337 in the 20 mg/kg IgG22 group maintained their weight throughout the duration of challenge, only losing 338 1% of the starting body weight on average by day 4 post-challenge ( Figure 7B) . On day 4 post-challenge, 339 mice that received 20 mg/kg IgG22 showed significantly lower (10.5-fold) lung SARS-CoV-2 than the 340 PBS control mice. In dose-dependent fashion, there was a modest 1.7-fold less SARS-CoV-2 titer in 341 lungs of mice immunized with 2 mg/kg IgG22 as compared to PBS ( Figure 7D ). There were negligible 342 differences in nasal turbinate SARS-CoV-2 titers (PFU/lobe) across all groups, suggesting that IgG22, at 343 up to 20 mg/kg, was insufficient in preventing viral replication in the upper airway ( Figure 7E ). In all, 344 the ability of IgG22 to prophylactically protect against both homotypic MERS-CoV and heterotypic 345 SARS-CoV-2 in mice shows promise for use of stabilized stem antigens, such as MERS SS, to induce not 346 only cross-reactive, but moreover protective antibody responses against related HCoVs. The efficacy of 347 IgG22 in heterotypic challenge additionally emphasizes the utility of such cross-reactive S2-directed 348 antibodies in acute prevention of coronavirus disease. 349

The S2 subunit of CoV S, analogous to HA2 of influenza virus HA and gp41 of HIV-1 Env, functions as 351 a fusogen by bringing viral and host cell membranes together, thus enabling viral entry. To mediate 352 fusion, the S2 subunit transitions from a metastable prefusion to a highly stable post-fusion conformation 353 (Li, 2016) . We previously reported that the introduction of stabilizing mutations into the S2 subunit of 354

stabilized trimeric full-length S retaining well-folded 3D structures resembling native S on the virion 356 J o u r n a l P r e -p r o o f surface (Hsieh et al., 2020; Ke et al., 2020; Kirchdoerfer et al., 2018; Pallesen et al., 2017; Turoňová et 357 al., 2020; Wrapp et al., 2020) . Importantly, neutralization-sensitive epitopes and host receptor-binding 358 sites in the S1 subunit were completely preserved. Collectively, the strategy of stabilizing S through 359 engineered prevention of S2 refolding has been successful for generating vaccine antigens that protect 360 animals in CoV-challenge models and humans from SARS-CoV-2 infection (Baden et al., 2020; Corbett 361 et al., 2020a Corbett 361 et al., , 2020b Polack et al., 2020) . In this study, we extended our structure-guided design strategy to generate MERS-CoV S2-only 373 antigens, with the intention of eliciting cross-reactive antibodies against conserved S2 epitopes. Using the 374 PROSS server (Goldenzweig et al., 2016) to identify candidate stabilizing mutations and biochemical 375 analyses to down-select expressed S2 mutant proteins, we arrived at two S2 subunit constructs optimized 376 for stability, conformational fidelity, and product yields as immunogens. Intra-protomer disulfide bonds 377 were the most effective means of enhancing protein expression and thermostability. The Cys803-Cys933 and HR1 to prevent the helix-loop region from transitioning to a single, elongated helix. Both Cys898 and 384

Cys1022 substitutions were at regions that move substantially, and a similar approach was employed to 385 increase the trimer fraction of HA stem (Cys68-Cys76) and to keep PIV3 F in a prefusion conformation 386 The cavity-filling approach proved to be successful in stabilizing loosely packed regions of RSV 394 F in its prefusion conformation (Krarup et al., 2015; McLellan et al., 2013) . We applied this tactic in the 395 optimization of a stable S2-only MERS immunogen by substituting Ser975 and Val983 with Met and Ile, 396 respectively, at the base of MERS-CoV SS. These changes neatly filled a hydrophobic pocket between 397 HR1 and amino acids that remain stationary during the pre-to post-fusion transition. A lone S975M 398 change proved to be the most effective, leading to more than 10-fold increase in protein yields relative to 399 the parental molecule. Similarly, N1132Y substitution seems to pack against Pro937, Val1206, and 400 Pro1131 and possibly forms H bonds with Gln800 and Asn1029. Other modifications intended to enhance 401 polar interactions-for instance, V958S, S1091E and L1094Q substitutions-were considered as 402 beneficial additions to our best construct. Alternative strategies, such as stabilizing proline substitutions, 403 reducing hydrophobicity at the S1-S2 interface, and nanoparticle display, are viable options to further 404 improve our MERS SS.V2 antigens in efforts to induce cross-neutralizing antibodies. 405 J o u r n a l P r e -p r o o f S proteins. To date, our study is the first to show protection against lethal MERS-CoV challenge with a 407 stem-only immunogen-protection that comes without elicitation of potent neutralizing antibody 408 responses. Previous studies suggest that in vivo activity of influenza virus stem-specific antibodies rely on 409

Fc-mediated functions (DiLillo et al., 2014 (DiLillo et al., , 2016 . In fact, only a handful of S2-specific neutralizing 410 antibodies against MERS-CoV have been defined (Wang et al., 2015; Widjaja et al., 2019) . One of these, 411 murine mAb G4, protects against challenge in a murine lethal model of MERS-CoV infection and binds a 412 hypervariable loop containing a unique N-glycosylation site in the connector domain (Pallesen et al., 413 2017; Wang et al., 2018) . Roughly one third of MERS-SS-reactive antibodies compete with G4 Fab for 414 the loop epitope, which suggests at least two types of neutralizing antibodies (G4-like and stalk-targeting) 415

were elicited by MERS-stem only antigens. Deletion of the highly immunogenic loop from an S2 subunit 416 vaccine might be advantageous to prevent natural immunofocusing on an epitope poorly conserved 417 among even closely related lineage C β-HCoVs. 418

Our study also describes a conserved epitope near the base of S, distinct from the G4-binding site. 419

Two antibodies that recognize this epitope, IgG22 and IgG72, display heterotypic binding to all highly 420 pathogenic β-HCoVs. Both antibodies neutralize authentic MERS-CoV and at low nM concentrations in 421 the case of IgG22. However, IgG72 demonstrated markedly reduced neutralizing activity against MERS-422

CoV as compared to IgG22 (approximately a 10-fold reduction in inhibitory titer). Cryo-EM structures of 423

Fab22 complexed with MERS S-2P and prefusion-stabilized SARS-CoV-2 S (HexaPro) revealed the Fab 424 binding site to be in close proximity to the helical portion of the stem, a region that is highly conserved 425 within betacoronaviruses. Although the binding interface was incompletely resolved in the cryo-EM 426 maps, we were able to obtain high-resolution crystal structures of stalk peptide-Fab22 complexes, which 427 revealed a conserved binding modality of the stalk-targeting antibody. The Fab22 binding site is within a 428 stem helix that must dramatically refold to form a six-helix bundle with HR1, which leads to virus-cell 429 fusion. Sequence alignments of Fab22 and Fab72 reveal only four amino acid differences-one in CDR-430 J o u r n a l P r e -p r o o f L3 and three in CDR-H2-and none of them directly interact with the stem helix, plausibly explaining 431 shared binding profiles for HCoV S proteins ( Figure S6C ). The faster (nearly 100-fold) dissociation rate 432 of Fab22 for HexaPro (and SARS-CoV S-2P) compared to MERS-CoV S-2P provides an explanation for 433 the undetectable heterotypic neutralizing activity by IgG22 (and IgG72). We note that similar antibodies 434 have been recently described (Pinto et al., 2021; Sauer et al., 2021; Zhou et al., 2021) , although in these 435 cases sequential immunization was employed using full-length S proteins from divergent β-CoVs to 436 induce a response to the conserved S2. 437

We explore the potential function of the cross-reactive antibody, IgG22, by assessing its ability to 438 provide protection in lethal challenge models of MERS-CoV and SARS-CoV-2. Though mAb G4 has 439 been shown to induce protection at 20 mg/kg in mouse models (Wang et al., 2018) , here we confirm its 440 specificity for MERS-CoV and demonstrate that IgG22 at the equivalent dose protects against not only 441 homologous challenge but additionally a SARS-CoV-2 lethal challenge. The specificity of mAb G4 442 toward a highly variable glycosylated loop in the generally well-conserved S2 domain of MERS-CoV 443 (Pallesen et al., 2017) may help explain its failure to both cross-react and to protect against SARS-CoV-2 444 challenge. Our studies reveal that unlike G4, IgG22 recognizes a highly conserved site in S2 that drives 445 virus-cell fusion, which provides a rationale for why targeting this site protects against other -CoVs. 446

Though our studies demonstrated that IgG22 fails to neutralize authentic SARS-CoV-2, it significantly 447 reduced tissue damage and lung discoloration scores compared to untreated mice and promoted rapid 448 clearance of virus from the lower respiratory tract. Passive administration of IgG22 did not reduce virus 449 replication in the upper respiratory tract, corroborating recent findings that the threshold for IgG-mediated 450 inhibition of SARS-CoV-2 replication is lower for lung than upper airways (Corbett et al., 2021) . These 451 findings emphasize the importance of determining other functional mechanisms by which non-452 neutralizing antibodies protect, especially in the context of cross-protection. Identifying the conserved 453

IgG22 binding site may inform future vaccine designs needed to manage not only the ongoing pandemic 454 but allow for the development of more broad vaccines to combat future spillovers of novel CoVs into 455 J o u r n a l P r e -p r o o f humans. Identification of sites, like IgG22's binding epitope, that cannot freely accumulate substitutions 456 to avoid loss-of-function mutations enables vaccine development efforts to target sites less likely to 457 escape antibody-mediated protection. As current vaccines employ full-length SARS-CoV-2 S antigens, 458 the immunodominant RBD and NTD skew humoral responses upon immunization-which may have 459 reduced activity against SARS-CoV-2 VOCs harboring conformational changes in the S1 domain. 460

Utilizing stem antigens may lessen the selective pressure for advantageous substitutions in the regions 461 which are responsible for interacting directly with host cells. 462

In summary, this study provides proof-of-concept that the CoV S stem can be rationally 463 engineered as a stabilized immunogen to elicit antibodies cross-reactive with all three epidemic β-HCoVs 464 and to provide complete protection in animals against a lethal MERS-CoV challenge. Using a stabilized 465 stem construct, we induced the production of antibodies which enabled the identification of a site of 466 vulnerability in the S2 subunit, which will inform development of next-generation CoV vaccines and 467

fortify CoV pandemic preparedness. 468

One limitation of this study is the lack of structural data showing the extent to which the 470 stabilizing mutations in the MERS-CoV S2 subunit favor the prefusion conformation. Further structure-471 based design focused on stabilizing the trimer interface could potentially lead to more native-like S2 472

immunogens. In addition, optimizing the helical stalk regions where the cross-protective antibodies bound 473 could be an alternative approach to design next-generation pan-coronavirus vaccines. Another limitation 474 is that the immunogen did not provide cross-protection for animals against SARS-CoV-2 infection. 475

Elicitation of broadly neutralizing or protective sera is desirable, but these first-generation immunogens 476

were unable to meet that standard. Although IgG22 provided protection in mice against both MERS-CoV 477 and SARS-CoV-2 challenge, additional immunogenicity studies conducted in non-human primates need 478

to be performed to strengthen this conclusion. between all groups. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001, **** = p-value < 541 0.0001. 542

See Figure S3 and S4 543 In (B) to (H), experimental groups were compared by one-way ANOVA with Kruskal-Wallis post-test. * 558 = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001, **** = p-value < 0.0001. 559 IgG20, IgG22 and IgG72 were tested in duplicate, and remaining mAbs were tested once. Neutralizing 567 mAb G4 was included as a positive control and tested in triplicate. 568 (E) Neither IgG22 nor IgG72 exhibited detectable neutralization of SARS-CoV-2. mAb S309, which 569 neutralizes SARS-CoV-2, was included as a positive control. IgG22 and IgG72 were tested once, and 570 S309 was tested in duplicate. See Figure S5 and Table S1 . (D) Binding of Fab22 to three SARS-CoV-2 S variants captured by RBD-directed IgG S309 is assessed 584 by BLI. Binding data are shown as black lines and the best fit to a 1:1 binding model is shown as red 585

See Figure S5 and Table S1 . 587 J o u r n a l P r e -p r o o f with the side chains shown as sticks. 596

(E) Alignment of the stem helix region of spike proteins from multiple betacoronaviruses. Fab22 interface 597 residues conserved between MERS-CoV and SARS-CoV-2 are denoted with a red dot. 598

See Figure S6 and Table S2 . 

Further information and requests for resources and reagents should be directed to and will be fulfilled by 617 the Lead Contact, Jason McLellan (jmclellan@austin.utexas.edu). 618

All unique/stable reagents generated in this study are available from the Lead Contact with a completed 620 Materials Transfer Agreement.  Any additional information required to reanalyze the data reported in this paper is available from the 628 lead contact upon request. 629

FreeStyle293F mammalian cells (ThermoFisher) were maintained in FreeStyle293 expression medium 632 (ThermoFisher) in a 37°C shaker supplied with 8% CO2 and 80% humidity. Huh7.5, Vero81, and Vero 633 E6 cells were incubated in DMEM (ThermoFisher) at 37°C and 5% CO 2. 634

Female BALB/cJ mice and C57BL/6J mice aged 6-to 8-weeks were obtained from Jackson Laboratory. 636

Female 10-week-old BALB/c were obtained from Envigo (BALB/cAnNHsD; stock # 047). Sixteen to 20-637

week-old male and female 288/330 +/+ mice were generated in the Baric Laboratory. All mouse 638

PHENIX: building new software for automated crystallographic structure determination

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates

Broadly neutralizing hemagglutinin stalkspecific antibodies require FcγR interactions for protection against influenza virus in vivo

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Coot: Model-building tools for molecular graphics

How good are my data and what is the resolution?

Automated Structure-and Sequence-Based Design of Proteins for High Bacterial Expression and Stability

Controlling the SARS-CoV-2 Spike Glycoprotein Conformation

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

High-throughput analysis of single hematopoietic stem cell proliferation in microfluidic cell culture arrays

A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice

Structure, Function, and Evolution of Coronavirus Spike Proteins

Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packing

Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation

Phaser crystallographic software

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

Structural basis for broad coronavirus neutralization

Evaluation of candidate vaccine approaches for MERS-CoV

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

A thermostable, closed SARS-CoV-2 spike protein trimer

A protective broadly cross-reactive human antibody defines a conserved site

The base construct used for the S2 subunit of MERS-CoV S-2P variant contained residues 762-1291 of 647 MERS-CoV S (GenBank ID: AFY13307) with proline substituted at residues 1060 and 1061, the foldon 648 trimerization motif of T4 fibritin, an HRV3C protease recognition site, an octa-histidine tag, and a tandem 649Twin-Strep-tag, cloned into the mammalian expression plasmid pαH. All mutations in subsequent designs 650 were introduced into this base construct. The initial design was conducted via the PROSS server 651 (Goldenzweig et al., 2016) , and a total of 11 substitutions were picked (yielding the 'mut11' construct) 652 from 53 computational designs based on the biochemical property of the residues and steric effect on the 653 prefusion-stabilized MERS S-2P structure (PDB ID: 5W9I). Using structure-based design, additional 654 substitutions that were aimed at favoring the stability of the prefusion structure were introduced into the 655 mut11 backbone. Pairs of core-facing residues less than 5 Å apart were replaced with aromatic sidechains 656 or pairs of aromatic and positively charged sidechains to favor pi-pi or pi-cation interactions, respectively. 657Alternatively, residues were replaced with extended or bulkier hydrophobic sidechains in efforts to fill 658 pre-existing internal cavities. Disulfide bonds were designed to increase overall stability of prevent 659 formation of the postfusion conformation. The charged or polar substitutions were aimed to establish 660 hydrogen bonds or salt bridges with the native residues that were predicted to be within 4.0 Å. To 661 examine the effect of the substitutions in the mut11 backbone, the mutations were individually or 662 combinatorially reverted back to the wild-type sequence. Three designs, each containing 5-7 of the 663 J o u r n a l P r e -p r o o f beneficial substitutions from the PROSS server (mut5, mut6 and mut7) were chosen to serve as 664 backgrounds for subsequent rounds of design. These were then combined with individual substitutions or 665 combinations of substitutions from the structure-based designs that were shown to be beneficial, for 666 subsequent assessment of improved monodispersity and thermostability. Substitutions predicted to 667 potentially interfere with one another or clash with native residues were avoided. 668

Plasmids encoding MERS SS variants were transiently transfected into FreeStyle293F cells (Thermo 670Fisher) using polyethyleneimine, with 5 μM kifunensine being added 3h post-transfection. Cultures were 671 grown for 6 days, and culture supernatant was separated via centrifugation and passage through a 0.22 μm 672 filter. Protein was purified from supernatants using StrepTactin resin (IBA). MERS SS variants were 673 further purified by size-exclusion chromatography (SEC) using a Superose 6 increase 10/300 column (GE 674Healthcare) in a buffer composed of 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN 3 . For initial 675 purification and characterization, single-substitution and combinatorial variants were purified from 40 mL 676 CoV-2 MA10 . For 288/330 +/+ mice infected with MERS-CoV, mice were monitored 713 up to 5 days post-challenge, and were euthanized and lungs were collected to investigate lung 714 discoloration, viral burden, and nasal turbinate was collected from select mice to determine viral burden 715 in the upper airway as described above. For BALB/c mice infected with SARS-CoV-2, mice were 716 monitored up to 4 days post-challenge, and were euthanized and lungs were collected to investigate lung 717 discoloration, viral burden, and nasal turbinate was collected from select mice to determine viral burden 718 in the upper airway as described above. Sample size for animal experiments was determined on the basis 719 of criteria set by institutional ACUC. Experiments were neither randomized nor blinded. 720

HCoV S-2P-specific IgG in immunized mouse sera were quantified via enzyme-linked immunosorbent 722 assay (ELISA). Briefly, Nunc MaxiSorp 96-well plates (ThermoFisher) were coated with either MERS S-723 2P, SARS S-2P, SARS-CoV-2 S-2P, or HKU1 S-2P at 1 µg/mL in 1X PBS at 4°C for 16h. Sera dilutions 724were prepared in blocking buffer, which consisted of PBS-Tween 20 + 5% non-fat dairy milk, and diluted 725 serially at 1:100, four-fold, 8x. To eliminate foldon-specific binding, 50 µg/mL of foldon was added to 726 the dilutions and incubated for an hour at room temperature. After standard washes and blocks, goat anti-727 mouse IgG-horseradish peroxidase (HRP) conjugate (SigmaAldrich) was used as secondary antibody. 728Plates were reacted with 3,5,3'5'-tetramethylbenzidine (TMB) (KPL) to detect binding responses. Plates 729 were read at OD 450/650 using SpectraMax Paradigm (Molecular Devices). Endpoint titers were calculated 730 as the reciprocal serum dilution that yielded a signal 4x greater than that of the background signal 731 (secondary antibody alone). 732

Neutralization activity was assessed as previously described (Pallesen et al., 2017) . Briefly, Huh7.5 cells 734were seeded at 10,000 cells/well in 96-well black/white Isoplates (PerkinElmer) 24-h prior to infection. 735Sera were serially diluted (1:40, 4-fold dilutions, 8x) in DMEM (Gibco) + 1% penicillin/streptomycin, 736 and mixed with a pseudotyped MERS-CoV England1 lentivirus reporter that was previously titrated to 737 J o u r n a l P r e -p r o o f 10 4 RLU, and incubated for 30 minutes at room temperature. The sera + pseudovirus mixture was then 738 added to Huh7.5 cells in duplicate, and incubated at 37°C and 5% CO 2 for 2h. Then, 100 µL of DMEM 739 supplemented with 10% FBS, 2 mM glutamine, and 1% penicillin/streptomycin was added to each well, 740and incubated for 72h. Cells were then lysed, and luciferase substrate (Promega) was added. Luciferase 741 activity was measured as relative luciferase units (RLU) at 570 nm, using a SpectraMaxL (Molecular 742 Devices). Sigmoidal curves, taking averages of triplicates at each dilution, were generated from RLU 743 readings; 50% neutralization (ID 50 ) titers were calculated considering uninfected cells as 100% 744 neutralization and cells transduced with only virus as 0% neutralization, by fitting RLU readings to a 745 log(agonist) vs. normalized-response (variable slope) nonlinear regression model in Prism v9 (GraphPad). 746

Immunized mice exhibiting elevated serum titers were sacrificed and plasma cells from lymph node, 748 spleen, and bone marrow tissues were isolated using standard protocols. Samples were screened with 749AbCellera's high-throughput single-cell microfluidic platform using a multiplexed microbead assay on 750 devices containing individual nanoliter-volume reaction chambers (Lecault et al., 2011) . The multiplexed 751 assay employed multiple optically-encoded beads, each conjugated to one of the following unique 752 antigens: full-length pre-fusion stabilized S proteins of MERS-CoV, SARS-CoV, or HKU1-CoV, or the 753 S2 subunit of MERS-CoV S. Bead-conjugated bovine serum albumin (BSA) His-tag and T4 foldon 754 trimerization domain were used as negative controls. Beads were flowed into microfluidic screening 755 devices and incubated with single antibody-secreting cells, and monoclonal antibody binding to cognate 756 antigens was detected via a fluorescently labeled anti-human IgG secondary antibody. Positive hits were 757 identified using machine vision and recovered using automated robotics-based protocols. 758

For recovery of paired heavy and light chain sequences, single-cell polymerase chain reaction (PCR) and 760next-generation sequencing (MiSeq, Illumina) were performed using automated workstations (Bravo, 761 Agilent) and custom molecular biology protocols. Sequences were analyzed using a custom 762 J o u r n a l P r e -p r o o f bioinformatics pipeline to yield paired heavy and light chain sequences for each recovered antibody-763 secreting cell. Each sequence was assigned the closest germline (V(D)J) genes, degree of somatic 764 hypermutation, and potential sequence liabilities. 765

Twenty monoclonal antibodies discovered by single B cell technology were selected for characterization 767 based on their binding specifies to HKU1-S, MERS-S and SARS-1-S (monospecific, bi-specific or tri-768 specific), diversity of heavy and light chain CDR3s, and high frequency rates in the B cell repertoire 769 (independently isolated by the probes more than 2 times). The individual VH sequence of selected IgGs 770 was cloned into a mammalian expression plasmid pVRC8400 containing HRV 3C cleavage site in the 771 hinge, and human IgG1 Fc domain. VL sequences were also cloned into pVRC8400 with human CL. 772Paired VH and VL in a 1:1 ratio were co-transfected transiently into FreeStyle293F cells as previously 773

A agarose (ThermoFisher). IgGs were eluted with 100 mM glycine, pH 3 into 1/10th volume 1 M Tris-775HCl pH 8.0. IgGs were then buffer exchanged into PBS pH 7.4. Fab fragments were generated by 776 digesting the IgGs with HRV 3C protease at 4 °C. Fc was removed by passing digests over a fresh Protein 777 A agarose, leaving the Fab in the flowthrough, which was further purified by SEC using a Superdex 200 778 increase 10/300 column (GE Healthcare) in PBS buffer, pH 7.4. 779

The binding affinity of purified IgGs to HKU1-CoV S, MERS-CoV S or SARS-CoV S was characterized 781 by BLI using an Octet RED96e (FortéBio). Briefly, anti-human Fc (AHC) sensors (FortéBio) with 782 captured IgG were dipped into the wells containing 100 nM of CoV S in a BLI buffer composed of 10 783 mM HEPES pH 7.4, 150 mM NaCl, 0.005% v/v Tween 20 and 1 mg/ml BSA. After 600s association 784 step, the dissociation step was carried out in the wells containing only BLI buffer for 600s. RSV F-foldon 785 was also included in the experiments as negative control. The binding affinity of purified mAb G4 to 786 MERS-CoV S and MERS SS was also characterized by BLI using similar approach. AHC sensors with 787 J o u r n a l P r e -p r o o f captured mAb G4 were dipped into the wells containing serial dilutions of MERS-CoV S or MERS SS at 788 concentration ranging from 100 to 1.56 nM in a BLI buffer. The data were aligned to a baseline prior to 789 association step and fit to a 1:1 binding model to calculate rate and dissociation constants using Octet 790 Data Analysis software v11.1. The IgGs exhibiting binding to MERS-CoV S was further examined for the 791 ability to compete with mAb G4, the only S2-targed antibody MERS-S antibody with a defined epitope 792 (Pallesen et al., 2017) . Four-fold molar excess of G4 Fab was preincubated with 100 nM MERS-S at 793 room temperature for 10 min. The IgG being tested was loaded on AHC sensors and then dipped into 50 mM NaOH and followed by 0.5 mM NiCl 2 . Response curves were double-reference subtracted and fit 806 to a 1:1 binding model using Biacore X100 Evaluation Software (GE Healthcare). 807

Four-fold serial dilutions of mAbs were combined with an average of 124 plaque-forming units of for 20 min at 37 o C, and 100 μl of virus-mAb mixture was applied to each of two confluent Vero 81 or 812 J o u r n a l P r e -p r o o f Vero E6 cell monolayers, respectively, in 6-well (10-cm 2 ) plates. Monolayers were overlaid with 813 Dulbecco's modified Eagle's medium (DMEM) containing 1% agar following virus adsorption for 30 min 814at 37 o C, and plaques were enumerated at 72 h or 96 h post-infection. Percent plaque reduction resulting 815 from mAb treatment (relative to untreated virus control) was plotted as a function of log 10 mAb 816 concentration. Neutralization data were subjected to five-parameter logistic regression modeling using 817 PRISM 9 (GraphPad). Minimum mAb concentrations resulting in 50% and 80% virus neutralization were 818 interpolated from fitted dose-response curves. 819

Purified MERS-CoV S-2P or SARS-CoV-2 S-HexaPro were incubated with 2-fold molar excess of Fab22 821 or Fab72 or Fab20 in 2 mM Tris pH 8.0, 200 mM NaCl and 0.02% NaN 3 at room temperature for 30 min. 822The S-Fab complexes were diluted to a concentration of 0.06 mg/mL in 2 mM Tris pH 8.0, 200 mM NaCl 823 and 0.02% NaN3. Each protein complex was deposited on a CF-400-CU grid (Electron Microscopy 824 Sciences) that had been plasma cleaned for 30 seconds in a Solarus 950 plasma cleaner (Gatan) with a 4:1 825 ratio of O 2 /H 2 and stained using methylamine tungstate (Nanoprobes). Grids were imaged at a 826 magnification of 92,000X (corresponding to a calibrated pixel size of 1.63 Å/pix) in a Talos F200C TEM 827 microscope equipped with a Ceta 16M detector (Thermo Fisher Scientific). The CTF-estimation and 828 particle picking were performed in cisTEM (Grant et al., 2018) . Particles were then imported into 829 cryoSPARC v2.15.0 for 2D classification (Punjani et al., 2017) . 830

Purified MERS-CoV S-2P at 1 mg/mL was incubated with 2-fold molar excess of Fab22 in 2 mM Tris pH 832 8.0, 200 mM NaCl and 0.02% NaN 3 at room temperature for 30 min. Sample was then deposited on a 833 plasma-cleaned CF-400 1.2/1.3 grid before being blotted for 5 seconds with +1 force in a Vitrobot Mark 834 IV (ThermoFisher) and plunge-frozen into liquid ethane. Similarly, purified SARS-CoV-2 S (HexaPro 835 variant) complexed with 2-fold molar excess of Fab22 was diluted to a concentration of 0.37 mg/mL in 2 836 mM Tris pH 8.0, 200 mM NaCl, 0.02% NaN 3 and applied to plasma-cleaned CF-400 1.2/1.3 grids before 837 J o u r n a l P r e -p r o o f being blotted for 3.5 seconds with -4 force in a Vitrobot Mark IV and plunge-frozen into liquid ethane. 838For the Fab22-MERS S-2P sample, 4330 micrographs were collected from a single grid. For the Fab22-839HexaPro sample, 2,013 micrographs were collected from a single grid. FEI Titan Krios (ThermoFisher) 840 equipped with a K3 direct electron detector (Gatan) was used for imaging. Data were collected at a 841 magnification of 22,500x, corresponding to a calibrated pixel size of 1.07 Å/pix. A full description of the 842 data collection parameters can be found in Table S1 . Warp was used for motion correction, CTF 843 estimation, and particle picking (Tegunov and Cramer, 2019). The particle stack was then imported into 844 cryoSPARC v2.15.0, which was used to curate the particles via iterative rounds of 2D classification 845 (Punjani et al., 2017) . The final reconstructions were then arrived at via ab initio reconstruction, 846 heterogeneous refinement, and subsequently non-uniform homogeneous refinement of final classes. The 847 structure validation can be found in Figure S5 . 848

To crystallize the Fab22+MERS stem helix peptide complex, MERS stem helix peptide 850 (DFQDELDEFFKNVST, GenScript) was added in 4-fold molar excess to Fab22, resulting in a final 851 concentration of 14 mg/ml Fab22 and 2 mg/ml peptide in 2 mM Tris pH 8, 200 mM NaCl, 0.02% NaN 3 . 852Peptide complex (0.1 μl) was mixed with 0.1 μl mother liquor (10% PEG1000, 10% PEG8000) using an 853 NT8 (Formulatrix), and the 0.2 μl drop was spotted onto an MRC2 crystallization tray to allow for vapor 854 diffusion, with 60 μl mother liquor in the well. For the SARS-CoV-2 stem helix peptide complex, a 855 modified version of Fab22 containing a mutation in the light chain constant Ig domain (C L ) that favors 856Fab crystallization was used (LCmod-Fab22, HQGLSSP to QGTTS) (Lieu et al., 2020) . SARS-CoV-2 857 stem helix peptide (DSFKEELDKYFKNHTSPDVD, GenScript) was added in 5-fold molar excess to 858LCmod-Fab22, resulting in a final concentration of 11 mg/ml LCmod-Fab22 and 2.1 mg/ml peptide in 2 859 mM Tris pH 8, 200 mM NaCl, 0.02% NaN 3 . Peptide complex (0.1 μl) was mixed with 0.05 μl mother 860 liquor (0.1 M sodium citrate pH 5.5, 23% PEG8000) using an NT8 (Formulatrix), and the 0.15 μl drop 861 was spotted onto an MRC2 crystallization tray to allow for vapor diffusion, with 60 μl mother liquor in 862 J o u r n a l P r e -p r o o f the well. Crystals were rapidly soaked in their respective mother liquors supplemented with 30% ethylene 863 glycol, looped, and flash-frozen in liquid nitrogen. Remote data collection was performed at the SBC 864 beamline 19ID (Advanced Photon Source, Argonne National Laboratory). Diffraction data were indexed 865 and integrated in iMOSFLM (Battye et al., 2011) , before being merged and scaled (to 2.4 Å for MERS 866 peptide complex and to 1.9 Å for SARS-CoV-2 peptide complex) using Aimless (Evans and Murshudov, 867 2013) . Molecular replacement was performed in Phaser (McCoy et al., 2007) , and models were then 868 subjected to multiple rounds of model building and refining in Coot and Phenix, respectively (Adams et 869 al., 2002; Emsley and Cowtan, 2004) . Data collection and refinement statistics can be found in Table S2 . used. Serum IgG endpoint titers and pseudovirus neutralizing antibody titers were transformed so that all 875 values were on a log(10) scale prior to statistical analyses. All one-way ANOVA analyses did not assume 876Gaussian distribution and were performed as non-parametric tests. One-way ANOVA analyses with 877Kruskal-Wallis post-tests corrected for multiple comparisons using statistical hypothesis testing via 878Dunn's tests. For one-way ANOVA, p-values are summarized within figures as: * < 0.05, ** < 0.01, *** 879 < 0.001, **** <0.0001. For comparisons of serum IgG endpoint titers ( Figure 2B-E) , two-way ANOVA 880 analyses were performed between groups receiving the same dose of different immunogens, and between 881 groups receiving the same immunogen at different doses. Two-way ANOVA analyses with multiple 882comparisons compared values within each row across columns; i.e. each cell mean was compared with 883 every other cell mean within their respective row. Corrections for multiple comparisons using statistical 884 hypothesis testing were performed via Sidak tests for all two-way ANOVA analyses. For two-way 885 ANOVA, p-values are summarized within figures as: * < 0.05, ** < 0.01, *** < 0.001, **** <0.0001. All 886 statistical analyses were conducted using Graphpad Prism v9.0.2, i.e., geometric mean titers (GMT), 887 J o u r n a l P r e -p r o o f means, and SEM (standard error of the mean) for serum IgG endpoint titers, pseudovirus neutralization 888 titers, plaque reduction neutralization titers, body weight loss of mice in challenge assessments, mouse 889 lung viral loads, and discoloration scores. 890 J o u r n a l P r e -p r o o f